Revumenib is a small molecule commercialized by Syndax Pharmaceuticals, with a leading Phase II program in Relapsed Acute Myeloid Leukemia. According to Globaldata, it is involved in 7 clinical trials, of which 4 are ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Revumenib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Revumenib is expected to reach an annual total of $165 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Revumenib Overview

SNDX-5613 is under development for the treatment of genetically-defined subset of acute leukemias with chromosomal rearrangements in the MLL gene such as relapsed and refractory acute lymphoblastic leukemia, acute myelobalstic leukemia and unresectable metastatic microsatellite stable colorectal cancer. It is administered orally. The drug candidate acts by targeting interaction of menin with the mixed lineage leukemia (MLL) protein and by inhibiting nucleophosmin (NPM1).

Syndax Pharmaceuticals Overview

Syndax Pharmaceuticals (Syndax) is a biopharmaceutical company that discovers, develops, and commercializes therapies for multiple cancer indications. The company’s product portfolio includes SNDX-5613, a novel orally menin-MLL1 inhibitor used for the treatment of MLLr or mNPM1 acute leukemias; and SNDX-6352 (Axatilimab), a colony stimulating factor 1 receptor (CSF-1R) to treat chronic graft versus host disease (cGVHD). It is also evaluating entinostat (SNDX-275), a class I HDAC inhibitor against multiple solid tumors. Syndax product candidate are also used for the treatment of non-small cell lung cancer, and melanoma, ovarian cancer and other indications. The company has an operational presence in the UK. Syndax is headquartered in Waltham, Massachusetts, the US.

The company reported revenues of (US Dollars) US$139.7 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$1.5 million in FY2020. The operating profit of the company was US$26.2 million in FY2021, compared to an operating loss of US$71.4 million in FY2020. The net profit of the company was US$24.9 million in FY2021, compared to a net loss of US$73.2 million in FY2020.

For a complete picture of Revumenib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.